EP1183259A2 - Derives d'azepinoindol, preparation et utilisation desdits derives - Google Patents

Derives d'azepinoindol, preparation et utilisation desdits derives

Info

Publication number
EP1183259A2
EP1183259A2 EP00974379A EP00974379A EP1183259A2 EP 1183259 A2 EP1183259 A2 EP 1183259A2 EP 00974379 A EP00974379 A EP 00974379A EP 00974379 A EP00974379 A EP 00974379A EP 1183259 A2 EP1183259 A2 EP 1183259A2
Authority
EP
European Patent Office
Prior art keywords
alkyl
phenyl
compounds
formula
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00974379A
Other languages
German (de)
English (en)
Inventor
Wilfried Lubisch
Michael Kock
Thomas Höger
Roland Grandel
Reinhold Müller
Sabine Schult
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946289A external-priority patent/DE19946289A1/de
Priority claimed from DE10039610A external-priority patent/DE10039610A1/de
Application filed by BASF SE filed Critical BASF SE
Publication of EP1183259A2 publication Critical patent/EP1183259A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to novel azepinoindole derivatives, their preparation and their use as inhibitors of the enzyme poly (ADP-ribose) poly erase or PARP (EC 2.4.2.30) for the production of medicaments.
  • ADP-ribose enzyme poly
  • PARP EC 2.4.2.30
  • PARP Poly (ADP-ribose) polymerase
  • PARS poly (ADP-ribose) synthase
  • PARP is believed to play a role in repairing DNA breaks (M.S. Satoh et al., Nature 1992, 356, 356-358). Damage or breakage of the DNA strands activate the enzyme PARP, which, when activated, catalyzes the transfer of ADP-ribose from NAD (S. Shaw, Adv. Radiat. Biol., 1984, 11, 1-69).
  • Nicotinamide is converted back into NAD by other enzymes using the energy source ATP. Overactivation of PARP would accordingly result in an unphysiologically high consumption of ATP and in extreme cases this leads to cell damage and cell death.
  • radicals such as superoxide anion, NO and hydrogen peroxide can lead to DNA damage in cells and thus activate PARP.
  • the formation of large amounts of radicals is observed in a number of pathophysiological conditions and it is assumed that this accumulation of radicals leads to or contribute to the observed damage to the cells or organs.
  • ischemic conditions of organs such as in stroke, heart attack (C. Thiemermann et al., Proc. Natl. Acad. Sei. USA, 1997, 94, 679-683) or ischemia of the kidneys, but also reperfusion damage such as this for example, after lysis of a heart attack (see above: C. Thiemermann et al.).
  • Inhibition of the PARP enzyme could therefore be a means to at least partially prevent or mitigate this damage.
  • PARP inhibitors could thus represent a new therapeutic principle for the treatment of a number of diseases.
  • the enzyme PARP influences the repair of DNA damage and could therefore also play a role in the therapy of cancer diseases, since in combination with cytostatically active substances a higher activity potential against tumor tissue was observed (G. Chen et al. Cancer Chemo. Pharmacol 1988, 22, 303).
  • tumors are leukemia, glioblassomas, lymphomas, melanomas, mom and cervical cancers.
  • PARP is involved in immunological diseases or diseases in which the immune system plays an important role, such as rheumatoid arthritis and septic shock, and that PARP inhibitors can have a favorable effect on the course of the disease (H Kroger et al. Infammation 1996, 20, 203-215; W. Ehrlich et al. Reumatol. Int. 1995, 15, 171-172; C. Szabo et al., Proc. Natl. Acad. Sei. USA 1998, 95, 3867-3872; S. Cuzzocrea et al. Eur. J. Pharmacol. 1998, 342, 67-76).
  • PARP in the sense of this invention is also understood to mean isoenzymes of the PARP enzyme described above.
  • WO 00/42040 lists azepinoindoles which inhibit the PARP enzyme.
  • there derivatives are described as effective which carry a phenyl ring in the 2-position which can still be substituted with simple substituents.
  • new azepinoindole derivatives of the general formula I are described, which are potent PARP inhibitors.
  • the present invention relates to substituted azepinoindole derivatives of the general formula I.
  • X 1 can be S, 0 and NH and
  • X 2 is a carbon atom that can still carry a chain C 1 -C 4 , and N and
  • X 3 can be N and CR 2 , where
  • R 2 is hydrogen, branched and unbranched Ci-C ⁇ -alkyl, -C-C 4 alkylphenyl, phenyl and
  • R 1 is hydrogen, chlorine, fluorine, bromine, iodine, branched and unbranched C 1 -C 6 -alkyl, OH, nitro, CF 3 , CN, NR 1: 1 R 12 ,
  • NH-CO-R 13 0-C ⁇ -C 4 alkyl, where R 11 and R 12 independently of one another are hydrogen or C 1 -C 4 -alkyl and R 13 is hydrogen, C 1 -C 4 -alkyl, C 1 -C 4 - Alkyl-phenyl or phenyl mean, and
  • X 4 can mean S, 0 or NH
  • F 1 can be a straight-chain or branched saturated or unsaturated carbon chain of 1 to 8 carbon atoms and
  • F 2 has the same meaning as F 1 independently of F 1 ,
  • G 3 is an unsaturated, saturated or partially unsaturated mono-, bi- or tricyclic ring with a maximum of 15 carbon atoms, an unsaturated, saturated or partially-unsaturated mono-, bi- or tricyclic ring with a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms ,
  • p can mean 0 and 1 and
  • q can be 0 and 1 and
  • r can be 0 and 1 and
  • R 41 is hydrogen, Ci-Cg-alkyl, where each carbon atom can still carry up to two radicals R 6 , phenyl, which can still carry a maximum of two radicals R 6 , and (CH 2 ) t -K and
  • R 43 is hydrogen and -C 4 alkyl
  • R 5 hydrogen, chlorine, fluorine, bromine, iodine, OH, nitro, CF 3 , CN, NR ll R l2 , NH-CO-R 13 , C ⁇ -C-alkyl-CO-NH-R 13 , COR 8 , Co -C -alkyl-0-CO-R 13 , -C-C -alkyl-phenyl, phenyl,
  • Ci-C ⁇ -alkyl C0 2 -C 4 -alkyl, and branched and unbranched Ci-C ⁇ -alkyl, 0-C ⁇ -C 4 alkyl, S-C ⁇ -C alkyl, each carbon atom of the alkyl chains having up to two radicals R 6 can wear and the alkyl chains can also be unsaturated, and R 6 hydrogen, chlorine, fluorine, bromine, iodine, branched and unbranched Ci-C ⁇ -alkyl, OH, nitro, CF 3 , CN, NR 1: L R 1 , NH-CO-R 13 , 0-C ⁇ -C - alkyl
  • R 7 is hydrogen, Ci-Cg-alkyl, phenyl, where the ring can still be substituted with up to two radicals R 71 , and an amine NR ⁇ R 12 or a cyclic saturated amine with 3 to 7 members, still with an alkyl -Ri Ci-Cg-alkyl may be substituted, and homopiperazine, which may also be substituted with an alkyl radical Ci-C ß- alkyl, and
  • R 11 , R 12 and R 13 in K, R 5 , R 6 and R 7 can independently assume the same meaning as R 1 , and
  • R 7 ⁇ OH, C ! -C 6 alkyl, 0-C ⁇ -C 4 alkyl, chlorine, bromine, iodine, fluorine, CF 3 , nitro, NH 2 , and
  • R 8 Ci-C ⁇ - alkyl, CF 3 , phenyl, -CC 4 -alkyl-phenyl, where the ring can be substituted with up to two radicals R 81 , and
  • R 81 OH, Cx-Cg-alkyl, 0-C ⁇ -C 4 alkyl, chlorine, bromine, iodine, fluorine, CF 3 , nitro, NH 2 , and
  • R 9 are hydrogen, C 6 alkyl, C 1 -C 4 alkyl, phenyl, C0 2 -C ⁇ -C alkyl, phenyl, C0 2 -C ⁇ -C 4 alkyl, S0 2 -phenyl, COR 8 and Phenyl, where the phenyl rings can also be substituted with up to two radicals R 91 , and
  • R 91 can be OH, -C 6 alkyl, 0 -C 4 alkyl, chlorine, bromine, iodine, fluorine, CF 3 , nitro, NH 2 ,
  • A is a C ⁇ -C 2 chain, which may be substituted
  • X 1 represents 0
  • R 1 is hydrogen.
  • R 4 DF 1 o, ⁇ -G 2 -G 3 with G 3 is hydrogen and
  • the compounds of the formula I can be used as racemates, as enantiomerically pure compounds or as diastereomers. If enantiomerically pure compounds are desired, these can be obtained, for example, by carrying out a classic resolution with the compounds of the formula I or their intermediates using a suitable optically active base or acid.
  • Alkyl chains can each be branched or unbranched. Unbranched alkyl chains are preferred.
  • the invention also relates to compounds of the formula I which are mesomeric or tautomeric.
  • the invention further relates to the physiologically tolerable salts of the compounds I, which can be obtained by reacting compounds I with a suitable acid or base.
  • suitable acids and bases are listed, for example, in Progress in Pharmaceutical Research, 1966, Birkhäuser Verlag, Vol. 10, pp. 224-285. These include, for example, hydrochloric acid, citric acid, tartaric acid, lactic acid, phosphoric acid, methanesulfonic acid, acetic acid, formic acid, maleic acid, fumaric acid etc. or sodium hydroxide, lithium hydroxide, potassium hydroxide and tris.
  • Prodrugs are understood to mean those compounds which are metrabolized in vivo into compounds of the general formula I. Typical prodrugs are phosphates, carbamates of amino acids, esters and others.
  • azepinoindole derivatives I according to the invention can be prepared in various ways, e.g. described in WO 00/42040.
  • the substituted azepinoindole derivatives I contained in the present invention are inhibitors of the enzyme poly (ADP-ribose) polymerase or PARP (EC 2.4.2.30).
  • the inhibitory effect of the substituted azepinoindole derivatives I can be determined using an enzyme test already known in the literature, a Ki value being determined as the yardstick.
  • the azepinoindole derivatives I were measured in this way for the inhibitory effect of the enzyme poly (ADP-ribose) polymerase or PARP (EC 2.4.2.30).
  • substituted azepinoindole derivatives of the general formulas I are inhibitors of poly (ADP-ribose) polymerase (PARP) or, as it is also called, poly (ADP-ribose) synthase (PARS), and can therefore be used for the treatment and prophylaxis of diseases, which are associated with an increased enzyme activity of these enzymes serve.
  • PARP poly (ADP-ribose) polymerase
  • PARS poly (ADP-ribose) synthase
  • the compounds of the formulas I can be used for the production of medicaments for the treatment of damage after ischemia and for prophylaxis in the case of expected ischemia of various organs.
  • the present azepinoindole derivatives of the general formula I can then be used for the treatment and prophylaxis of neurodegenerative diseases following ischemia, trauma (craniocerebral trauma), mass bleeding, subarachnoid bleeding and stroke occur, and of neurodegenerative diseases such as multiple infarct dementia, Alzheimer's disease, Huntington's disease and epilepsy, in particular of generalized epileptic seizures such as petit mal and tonic-clonic seizures and partially epileptic seizures such as temporal lope and complex-partial Seizures, and further for the treatment and prophylaxis of damage to the heart after cardiac ischemia and damage to the kidneys after renal ischemia, for example acute renal insufficiency, caused by drug therapies such as cyclosporin treatment, the acute
  • Kidney failure or damage that occurs during and after a kidney transplant can be used for the treatment of acute myocardial infarction and damage which occurs during and after its drug lysis (for example with TPA, reteplase, streptokinase or mechanically with a laser or rotablator) and of micro-infarcts during and after heart valve replacement, aneurysm resections and serve heart transplants.
  • the present azepinoindole derivatives I can also be used to treat a revascularization of critically narrowed coronary arteries, for example in PCTA and bypass operations, and critically narrowed peripheral arteries, for example leg arteries.
  • azepinoindole derivatives I can be useful for the treatment of tumors and their metastasis and for the treatment of inflammation and rheumatic diseases such as e.g. rheumatoid arthritis and also for the treatment of diabetes mellitus, for the treatment of multi-organ failure e.g. in septic shock and for the treatment of ARDS (acute respiratory distress syndrome shock lung).
  • rheumatic diseases such as e.g. rheumatoid arthritis and also for the treatment of diabetes mellitus
  • multi-organ failure e.g. in septic shock and for the treatment of ARDS (acute respiratory distress syndrome shock lung).
  • the pharmaceutical preparations according to the invention contain a therapeutically effective amount of the compounds I.
  • the active compounds can be present in the usual concentrations.
  • the active substances are contained in an amount of 0.001 to 1% by weight, preferably 0.001 to 0.1% by weight.
  • the preparations are administered in single doses. 0.1 to 100 mg per kg body weight are given in a single dose.
  • the preparation can be administered daily in one or more doses depending on the type and severity of the diseases.
  • the pharmaceutical preparations according to the invention contain the usual carriers and diluents in addition to the active ingredient.
  • pharmaceutical-technical auxiliaries such as ethanol, isopropanol, oxyethylated castor oil, oxyethylated hydrogenated castor oil, polyacrylic acid, polyethylene glycol, polyethylene glycol stearate, ethoxylated fatty alcohols, paraffin oil, petroleum jelly and wool fat can be used.
  • Milk sugar, propylene glycol, ethanol, starch, talc and polyvinylpyrrolidone are suitable for internal use.
  • Antioxidants such as tocopherol and butylated hydroxyanisole and butylated hydroxytoluene, taste-improving additives, stabilizers, emulsifiers and lubricants can also be present.
  • the substances contained in the preparation in addition to the active substance and the substances used in the manufacture of the pharmaceutical preparations are toxicologically harmless and compatible with the respective active substance.
  • the pharmaceutical preparations are produced in a customary manner, for example by mixing the active ingredient with other customary excipients and diluents.
  • the pharmaceutical preparations can be in different
  • Application modes are administered, for example, orally, parenterally and intravenously by infusion, subcutaneously, intraperitoneally and topically.
  • Forms of preparation such as tablets, emulsions, infusion and injection solutions, pastes, ointments, gels, creams, lotions, powders and sprays are possible.
  • a 96-well microtiter plate (flacon) is coated with histones (Type II-AS; SIGMA H7755).
  • histones are dissolved in carbonate buffer (0.05 M NaHC0 3 ; pH 9.4) to a concentration of 50 ⁇ g / ml.
  • the individual wells of the microtiter plates are incubated overnight with 100 ⁇ l of this histone solution.
  • the histone solution is then removed and the individual wells are incubated with 200 ⁇ l of a 1% BSA (Bovine Serum Albumine) solution in carbonate buffer for 2 hours at room temperature. It is then washed three times with washing buffer (0.05% Tween10 in PBS).
  • BSA Bovine Serum Albumine
  • the enzyme reaction is started by adding 40 ⁇ l of a substrate solution (4 ⁇ l reaction buffer (see above), 8 ⁇ l NAD solution (100 ⁇ M in H 2 0), 28 ⁇ l H 2 0). Response time is 20 minutes at room temperature.
  • the reaction is stopped by washing three times with washing buffer (see above). This is followed by a one-hour incubation at room temperature with a specific anti-poly-ADP-Ribose antibody.
  • a monoclonal anti-poly (ADP-ribose) antibody "10H" (Kawamaitsu H et al. (1984) Monoclonal antibodies to poly (adenosine diphosphate ribose) recognize different structures. Biochemistry 23, 3771-3777) was used as the antibody. Polyclonal antibodies can also be used.
  • the antibodies were used in a 1: 5000 dilution in antibody buffer (1% BSA in PBS; 0.05% Tween20). After washing three times with washing buffer, there is a one-hour incubation at room temperature with the secondary antibody.
  • an anti-mouse IgG coupled with peroxidase Boehringer Mannheim
  • an anti-rabbit IgG coupled with peroxidase SIGMA A-6154
  • the color reaction is carried out using 100 ⁇ l / well color reagent (SIGMA, TMB ready mix, T8540) for approx. 15 min. at room temperature.
  • the color reaction is stopped by adding 100 ul 2 M HS0 4 . Then the measurement is carried out immediately (450 nm against 620 nm; ELISA plate reader "Easy Reader” EAR340AT, SLT-Labinstruments, Austria).
  • the IC50 value of an inhibitor to be measured lies at the inhibitor concentration, where a half-maximum change in color concentration occurs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés de formule (I), ainsi que leurs formes tautomères, et éventuellement leurs formes énantiomères et diastéréoisomères, des promédicaments contenant ces composés, la préparation et l'utilisation desdits composés, les valeurs de la formule (I) ayant la signification qui figure dans le descriptif.
EP00974379A 1999-09-28 2000-09-15 Derives d'azepinoindol, preparation et utilisation desdits derives Withdrawn EP1183259A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19946289A DE19946289A1 (de) 1999-09-28 1999-09-28 Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE19946289 1999-09-28
DE10039610A DE10039610A1 (de) 2000-08-09 2000-08-09 Azepinoindol-Derivate, deren Herstellung und Anwendung
DE10039610 2000-08-09
PCT/EP2000/009024 WO2001023390A2 (fr) 1999-09-28 2000-09-15 Derives d'azepinoindol, preparation et utilisation desdits derives

Publications (1)

Publication Number Publication Date
EP1183259A2 true EP1183259A2 (fr) 2002-03-06

Family

ID=26006691

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00974379A Withdrawn EP1183259A2 (fr) 1999-09-28 2000-09-15 Derives d'azepinoindol, preparation et utilisation desdits derives

Country Status (17)

Country Link
EP (1) EP1183259A2 (fr)
JP (1) JP2003510328A (fr)
KR (1) KR20010087401A (fr)
CN (1) CN1374961A (fr)
AU (1) AU1271201A (fr)
BG (1) BG105650A (fr)
BR (1) BR0007174A (fr)
CA (1) CA2352194A1 (fr)
CZ (1) CZ20012373A3 (fr)
HK (1) HK1048999A1 (fr)
HU (1) HUP0104917A3 (fr)
IL (1) IL143349A0 (fr)
NO (1) NO20012567L (fr)
PL (1) PL347885A1 (fr)
SK (1) SK8842001A3 (fr)
TR (1) TR200101499T1 (fr)
WO (1) WO2001023390A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1140936E (pt) 1999-01-11 2004-06-30 Agouron Pharma Inibidores triciclicos de poli(adp-ribose) polimerases
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU3652102A (en) * 2000-12-01 2002-06-11 Guilford Pharm Inc Compounds and their uses
US7026311B2 (en) 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
CA2482806A1 (fr) 2002-04-30 2003-11-13 Kudos Pharmaceuticals Limited Derives de phthalazinone
ATE405658T1 (de) 2002-07-26 2008-09-15 Basf Plant Science Gmbh Neue selektionsverfahren
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7223759B2 (en) 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
SG150548A1 (en) 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
KR20070083484A (ko) 2004-07-14 2007-08-24 피티씨 테라퓨틱스, 인크. Ｃ형 간염 치료 방법
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
NZ553329A (en) 2004-07-22 2010-09-30 Ptc Therapeutics Inc Thienopyridines for treating hepatitis C
EP1859037A2 (fr) 2005-03-08 2007-11-28 BASF Plant Science GmbH Sequences introniques facilitant l'expression
US7662824B2 (en) 2005-03-18 2010-02-16 Janssen Pharmaceutica Nv Acylhydrazones as kinase modulators
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
GB0804755D0 (en) * 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
EA020783B1 (ru) 2008-10-07 2015-01-30 Астразенека Юк Лимитед Фармацевтическая композиция, содержащая 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-он и коповидон
WO2011058367A2 (fr) 2009-11-13 2011-05-19 Astrazeneca Ab Test de diagnostic pour prédire la sensibilité à un traitement par un inhibiteur de poly(adp-ribose) polymérase
CN102762726A (zh) 2009-11-27 2012-10-31 巴斯夫植物科学有限公司 嵌合内切核酸酶及其用途
US9404099B2 (en) 2009-11-27 2016-08-02 Basf Plant Science Company Gmbh Optimized endonucleases and uses thereof
CA2781693C (fr) 2009-11-27 2018-12-18 Basf Plant Science Company Gmbh Endonucleases chimeriques et utilisations de celles-ci
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
EP3325623B3 (fr) 2015-07-23 2021-01-20 Institut Curie Utilisation d'une combinaison d'une molécule servant d'appât et d'inhibiteurs de parp pour le traitement du cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (fr) 2017-03-08 2018-09-13 Onxeo Nouveau biomarqueur prédictif de la sensibilité à un traitement du cancer avec une molécule dbait
AU2018260094A1 (en) 2017-04-28 2019-11-07 Akribes Biomedical Gmbh A PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
WO2018218025A1 (fr) * 2017-05-24 2018-11-29 The Trustees Of The University Of Pennsylvania Inhibiteurs de parp radiomarqués et fluorescents pour l'imagerie et la radiothérapie
EP3765613A1 (fr) 2018-03-13 2021-01-20 Onxeo Molécule dbait contre la résistance acquise dans le traitement du cancer
WO2020113094A1 (fr) 2018-11-30 2020-06-04 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation
WO2020156577A1 (fr) * 2019-02-02 2020-08-06 正大天晴药业集团股份有限公司 Analogue d'indolo-heptamyl-oxime en tant qu'inhibiteur de parp
WO2021018298A1 (fr) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 Composés acyloxime à sept chaînons indolo servant d'inhibiteurs de parp
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CN115698019A (zh) * 2020-07-31 2023-02-03 正大天晴药业集团股份有限公司 用作parp抑制剂的吲哚并七元酰肟类似物的结晶及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9298198A (en) * 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
PT1140936E (pt) * 1999-01-11 2004-06-30 Agouron Pharma Inibidores triciclicos de poli(adp-ribose) polimerases
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0123390A2 *

Also Published As

Publication number Publication date
SK8842001A3 (en) 2002-01-07
PL347885A1 (en) 2002-04-22
BG105650A (en) 2002-02-28
HUP0104917A3 (en) 2002-12-28
HUP0104917A2 (hu) 2002-04-29
BR0007174A (pt) 2001-09-04
CA2352194A1 (fr) 2001-04-05
WO2001023390A3 (fr) 2001-12-27
TR200101499T1 (tr) 2002-09-23
HK1048999A1 (zh) 2003-04-25
NO20012567L (no) 2001-06-25
WO2001023390A2 (fr) 2001-04-05
NO20012567D0 (no) 2001-05-25
CN1374961A (zh) 2002-10-16
IL143349A0 (en) 2002-04-21
CZ20012373A3 (cs) 2002-05-15
JP2003510328A (ja) 2003-03-18
AU1271201A (en) 2001-04-30
KR20010087401A (ko) 2001-09-15

Similar Documents

Publication Publication Date Title
EP1183259A2 (fr) Derives d'azepinoindol, preparation et utilisation desdits derives
EP1222191B1 (fr) Derives de benzodiazepine, preparation et utilisation desdits derives
EP1257551B1 (fr) Composes heterocycliques et leur utilisation comme inhibiteurs de parp
EP1133477B1 (fr) Benzimidazoles substitues et leur utilisation comme inhibiteurs de la parp
EP1171424B1 (fr) Benzimidazoles a substitution cycloalkyle, et leur utilisation comme inhibiteurs de la parp
EP1231982B1 (fr) Utilisation de derives de phtalazine pour le traitement des maladies neurodegeneratives
WO2001085687A1 (fr) Indoles substitues en tant qu'inhibiteurs de parp
EP1131301B1 (fr) 2-phenylbenzimidazoles et 2-phenylindoles, leur production et leur utilisation
EP1127052B1 (fr) 2-phenylbenzimidazoles substitues, leur preparation et leur utilisation
EP1040101B1 (fr) 2-aryl-4-aminoquinazolines substituees, leur procede de production et leur utilisation comme medicament
WO2000068206A1 (fr) Benzimidazoles substitues par voie heterocyclique, leur production et leur application
EP1131302B1 (fr) 4-amino-2-aryl-cyclopenta [d]pyrimidine substituee, sa fabrication, son utilisation et preparations pharmaceutiques la renfermant
DE19836697A1 (de) Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
EP1095015B1 (fr) N-arylamides d'acide sulfonylaminocarboxylique utilises comme activateurs de la guanylate cyclase
DE60301725T2 (de) Dibenzodiazepin derivate, deren herstellung und verwendung
DE60006936T2 (de) Substituierte 4-amino-2-aryltetrahydrochinazoline, deren herstellung, deren verwendung und diese enthaltende pharmazeutische zusammenstellungen
DE19916460B4 (de) Substituierte Benzimidazole, deren Herstellung und Anwendung
EP0621037A1 (fr) Composés pyrido-pyrimidinediones, leur préparation et leur utilisation pharmaceutique
DE10039610A1 (de) Azepinoindol-Derivate, deren Herstellung und Anwendung
MXPA01005199A (en) Azepinoindole derivatives, the production and use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010531

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT PAYMENT 20010531;LV PAYMENT 20010531;MK;RO PAYMENT 20010531;SI PAYMENT 20010531

17Q First examination report despatched

Effective date: 20020710

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABBOTT GMBH & CO. KG

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030121